Related Experiment Videos
[Effectiveness of cefotaxime in experimental plague infection]
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
|November 1, 1992
Abstract:
Cefotaxime was shown highly efficient in prophylaxis and treatment of experimental plague infection in albino mice. The in vitro activity of cefotaxime against natural strains of the plague microbe was 32 to 64 times higher than that of cefazolin, cephalothin and cefmetazole. The combined use of cefotaxime with amikacin significantly increased the percentage of the survived albino mice with plague infection as compared to the use of the antibiotics alone.
Insights
Cefotaxime demonstrates high efficacy in preventing and treating experimental plague in mice. Combining cefotaxime with amikacin further improved survival rates compared to single antibiotic treatments.
Area of Science:
- Microbiology and Infectious Diseases
- Pharmacology and Therapeutics
Context:
- Plague, a severe bacterial infection caused by Yersinia pestis, remains a significant public health concern.
- Evaluating novel and existing antibiotic therapies is crucial for effective plague prophylaxis and treatment.
Purpose:
- To assess the efficacy of cefotaxime in experimental plague infection models.
- To compare the in vitro activity of cefotaxime with other cephalosporins against plague bacteria.
- To investigate the synergistic effects of combining cefotaxime with amikacin for plague treatment.
Summary:
- Cefotaxime exhibited high efficiency in both prophylaxis and treatment of experimental plague in albino mice.
- In vitro studies revealed cefotaxime's activity against natural plague microbe strains was 32-64 times greater than cefazolin, cephalothin, and cefmetazole.
- Combined administration of cefotaxime and amikacin significantly enhanced survival rates in infected mice compared to monotherapy.
Impact:
- These findings highlight cefotaxime as a potent agent for plague management.
- The study suggests that combination therapy with amikacin could be a promising strategy to improve outcomes in plague patients.
- This research contributes valuable data for the development of optimized antimicrobial strategies against Yersinia pestis.